Gelteq shares rise 47.64% premarket after positive preclinical results show 22% higher CBD bioavailability vs. FDA-approved product.

Gelteq (NASDAQ: GELS) surged 47.64% in premarket trading, driven by positive preclinical results demonstrating a 22% increase in CBD bioavailability compared to an FDA-approved oil-based product, enhancing its competitive positioning in the medicinal cannabis sector. The company also highlighted plans to leverage Australia’s Special Access Scheme for expedited market entry, potentially accelerating revenue growth and partnership opportunities. This development underscores investor confidence in Gelteq’s oral gel delivery platform, which addresses critical absorption challenges in cannabinoid-based therapies. The sharp price increase aligns with the news, reflecting optimism about the company’s technological edge and regulatory pathway advancements.